Epidemiology and Role of Nonsteroidal Antiinflammatory Drugs in Causing Gastrointestinal Bleeding

Gastrointestinal Endoscopy Clinics of North America

Volumn 21, Issue 4, 2011, Pages 597-612

  Lee, Iris ^a   Cryer, Byron ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Epidemiology; Gastrointestinal tract; Injury; Nonsteroidal antiinflammatory drugs; Pathogenesis; Prevention

Indexed keywords

2,4 DINITROPHENOL; ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; HYDROGEN SULFIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MECLOFENAMIC ACID; MELOXICAM; NAPROXEN; NIMESULIDE; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; PROSTANOID; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLATE SODIUM; STOMACH SECRETION INHIBITOR; SULINDAC SULFIDE; TOLMETIN; UNINDEXED DRUG;

DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ENZYME INHIBITION; FEVER; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HELICOBACTER INFECTION; HOSPITALIZATION; HUMAN; HYDROPHOBICITY; MORBIDITY; MORTALITY; NONHUMAN; OSTEOARTHRITIS; PAIN; PATHOGENESIS; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH EROSION; STOMACH OBSTRUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL HEMORRHAGE; HUMANS;

EID: 80053182591     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2011.07.003     Document Type: Review

References (61)

1. Dai C., Stafford R.S., Alexander G. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005, 165:171-177.
2. Shaheen N.J., Hansen R.A., Morgan D.R., et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006, 101(9):2128-2138.
3. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120(3):594-606. [review].
4. Sostres C., Gargallo C.J., Arroyo M.T., et al. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010, 24(2):121-132.
5. Lanas A., Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006, 38(6):415-428.
6. Hernández-Díaz S., Rodríguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160(14):2093-2099.
7. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
8. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
9. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000, 284:1247-1255.
10. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364:665-674.
11. Tannenbaum H., Bombardier C., Davis P., Third Canadian Consensus Conference Group, et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006, 33(1):140-157.
12. Lanas A. A review of the gastrointestinal safety data-a gastroenterologist's perspective. Rheumatology (Oxford) 2010, 49(Suppl 2):ii3-ii10.
13. DeAbajo F.J., García-Rodríguez L.A. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001, 1:1.
14. Lanas A., García-Rodríguez L.A., Arroyo M.T., Asociación Española de Gastroenterología, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55(12):1731-1738.
15. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998, 105(1B):31S-38S.
16. Wallace J.L., McKnight W., Reuter B.K., et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000, 119:706-714.
17. Lanas A., García Rodriguez L.A., Polo-Tomas M., et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009, 104(7):1633-1641.
18. Brun J., Jones R. Non-steroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001, 110:12S-13S.
19. Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987, 28:527-532.
20. Larkai E.N., Smith J.L., Lidsky M.D., et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol 1987, 82:1153-1158.
21. Lanas A., Perez-Aisa M.A., Feu F., Investigators of the Asociación Española de Gastroenterología (AEG), et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 2005, 100(8):1685-1693.
22. Bruce B., Fries J. Longitudinal comparison of the Health Assessment Questionnaire (HAQ) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Arthritis Rheum 2004, 51(5):730-737.
23. Perez-Aisa M.A., Del Pino D., Siles M., et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005, 21(1):65-72.
24. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007, 102(5):1101-1107.
25. Hermansson M., Ekedahl A., Ranstam J., et al. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2001. BMC Gastroenterol 2009, 9:25.
26. Sung J.J., Kuipers E.J., El-Serag H.B. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009, 29(9):938-946. [review].
27. Schoen R.T., Vender R.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989, 86(4):449-458. [review].
28. Cryer B. The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Curr Gastroenterol Rep 2003, 5(6):453-458.
29. Lichtenberger L.M., Zhou Y., Dial E.J., et al. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006, 58(11):1421-1428. [review].
30. Lichtenberger L.M., Wang Z.M., Romero J.J., et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995, 1(2):154-158.
31. Somasundaram S., Sigthorsson G., Simpson R.J., et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000, 14(5):639-650.
32. Perini R., Fiorucci S., Wallace J.L. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can J Gastroenterol 2004, 18(4):229-236. [review].
33. Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997, 112(1):109-117.
34. Feldman M., Jialal I., Devaraj S., et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001, 37(8):2036-2041.
35. Cryer B. Reducing the risks of GI bleeding with anti-platelet therapies. N Engl J Med 2005, 352(3):287-289.
36. Konturek S.J., Konturek P.C., Brzozowski T. Prostaglandins and ulcer healing. J Physio Pharmacol 2005, 56(Suppl 5):5-31. [review].
37. Wallace J.L., Keenan C.M., Granger D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990, 259:G462-G467.
38. Wallace J.L., Arfors K.E., McKnight G.W. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 1991, 100:878-883.
39. Wallace J.L., McKnight W., Miyasaka M., et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 1993, 265:G993-G998.
40. Asako H., Kubes P., Wallace J.L., et al. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992, 262:G903-G908.
41. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996, 334:1435-1439.
42. Muscara M.N., Vergnolle N., Lovren F., et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000, 129:1423-1430.
43. Feldman M., Shewmake K., Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000, 279(5). G1113-20.
44. Singh G., Fort J.G., Goldstein J.L., TriadafilopoulosG, SUCCESS-I Investigators, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I. Am J Med 2006, 119(3):255-266.
45. Cryer B. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am 2001, 30(4):877-894. v-vi.
46. Cryer B., Spechler S.J. Peptic ulcer disease. Gastrointestinal and Liver Disease 2006, 1089-1110. WB Saunders Elsevier, Philadelphia. vol 1. 8th edition. M. Feldman, L.S. Friedman, M.H. Sleisenger (Eds.).
47. Scarpignato C., Hunt R. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010, 39(3):433-464.
48. Cryer B., Feldman M. Effects of analgesics and anti-inflammatory drugs on cyclooxygenase (COX)-1 and COX-2 activity in healthy humans. Gastroenterology 1997, 112(4):A95.
49. Warner T.D., Giuliano F., Vojnovic I., et al. Nonsteroid drug selectives for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999, 96(13):7563-7568. [erratum in: Proc Natl Acad Sci U S A 1999;96(17):9666].
50. Whittle B.J. Nitric oxide-modulating agents for gastrointestinal disorders. Expert Opin Investig Drugs 2005, 14(11):1347-1358.
51. Karlsson J., Pivodic A., Aguirre D., et al. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009, 36(6):1290-1297.
52. Wallace J.L. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol Sci 2007, 28(10):501-505.
53. Fiorucci S., Antonelli E., Distrutti E., et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 2005, 129(4):1210-1224.
54. Wallace J.L., Caliendo G., Santagada V., et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 2010, 159(6):1236-1246.
55. Sparatore A., Perrino E., Tazzari V., et al. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic Biol Med 2009, 46(5):586-592.
56. Bertolini A., Ottani A., Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharm Res 2001, 44(6):437-450. [review].
57. Raynauld J.P., Martel-Pelletier J., Haraoui B., et al. for the Canadian Licofelone Study Group. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Ann Rheum Dis 2011, 70(8):1382-1388.
58. Lichtenberger L.M., Barron M., Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 2009, 45(12):877-890.
59. Cryer B., Bhatt D.L., Lanza F.L., et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 2011, 106(2):272-277.
60. Chan F.K., Cryer B., Goldstein J.L., et al. The A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs though the entire GI tract. J Rheumatol 2010, 37(1):167-174.
61. Chan F.K., Lanas A., Scheiman J., et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010, 376(9736):173-179.